Loading clinical trials...
Loading clinical trials...
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotin...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT06974734 · Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, and more
NCT03128008 · Carcinoma, Non Small Cell Lung (NSCLC)
NCT00553254 · Carcinoma, Non Small Cell Lung
NCT01671332 · Carcinoma, Non Small Cell Lung
NCT00798720 · Carcinoma, Non Small Cell Lung
City of Hope
Duarte, California
City of Hope Medical Group
Pasadena, California
City of Hope South Pasadena Cancer Center
South Pasadena, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions